{
  "docId": "019dd923-5e88-73ef-bd5a-d62c891ad637",
  "docSlug": "d07ec288d5b21a01",
  "documentTitle": "2025 JP Morgan Healthcare Conference",
  "authorId": "JPMorgan",
  "authorName": "P&A Global",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 3,
  "pageCount": 3,
  "prevPage": 2,
  "nextPage": null,
  "slideType": "initiative_list",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "This appears to be a continuation slide (items 15-22) from a larger report.",
  "elementsJson": [
    "numbered_list",
    "logo_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-d62c891ad637/3",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.05,
        "y": 0.02
      },
      "kind": "image",
      "text": "P&A Global",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a93b2c0-f911-4f21-b509-9f6c921fdaa0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.15,
        "y": 0.15
      },
      "kind": "list",
      "text": "15. Inspire Medical Systems: Highlighted revenue growth and the approval of the Inspire V neurostimulation system. The company plans to expand its sales territories and launch new products in 2025.\n16. Recursion Pharmaceuticals: Emphasized its OS platform and oncology portfolio. The company plans to maximize the return on its business combination with Exscientia and achieve multiple milestones in 2025.\n17. Roivant Sciences: Focused on the potential of IMVT-1402 and Brepocitinib. The company anticipates multiple registrational trials and a strong capital position to achieve its goals.\n18. SpringWorks Therapeutics: Highlighted the success of Ogsiveo and the development of mirdametinib. The company plans for international launches and additional trials in 2025.\n19. Viking Therapeutics: Focused on the development of VK2735 for obesity and VK2809 for NASH. The company plans to initiate a Phase III program and achieve significant clinical milestones in 2025.\n20. Xenon Pharmaceuticals: Emphasized the development of azetukalner for epilepsy and MDD. The company anticipates key data readouts and regulatory submissions in 2025.\n21. Intellia Therapeutics: Highlighted its focus on NTLA-2002 and Nex-z for HAE and ATTR. The company plans to complete enrollment for its Phase III programs and prepare for regulatory submissions.\n22. Nuvation Bio: Reported progress in its oncology pipeline, including the approval of Taletrectinib in China. The company anticipates a commercial launch in the US and further clinical advancements in 2025.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96b1c207-49a1-4b0d-8364-22e0d05fc2db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.25,
        "y": 0.95
      },
      "kind": "paragraph",
      "text": "Proficiency . Partnership. Strategy . Results\nwww.paglobal.us",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a779c1e-a85e-4c82-babc-1bfe5d65dfe6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.75,
        "y": 0.03
      },
      "kind": "paragraph",
      "text": "+1 (210) 956 - 1505\n+1 (412) 606 - 4399\n400 E. Randolph Street Ste: 715-C\nChicago, IL 60601 U.S.A",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b7e473c-b013-4a75-b2d4-b36a483972e8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 2,
      "beatId": "99ad4a1b-6a50-4fae-935e-79e6d5c324e1",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The initiative lists provide evidence of industry updates and developments.",
      "position": 1,
      "confidence": 0.7,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}